Colorectal Cancer Survivor Symptom Management

Not Applicable

Completed

• Conditions: Colorectal Cancer; Survivorship
• Interventions: Other: CRCaSSM

• Registration Number: NCT05876338
• Lead Sponsor: Akdeniz University

Brief Summary

Objective: The aim of this study was to examine the effects of nursing interventions based on the symptom management model on symptom management, fear of recurrence, and quality of life in colorectal cancer survivors.

Method: The research was planned as a randomized controlled trial. The research is planned to be carried out at Akdeniz University Hospital. It is planned to be done with 52 patients, 26 experimental and 26 control groups. The intervention group will receive face-to-face training and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months. Participant Information Form, Memorial Symptom Assessment Scale, Fear of Cancer Recurrence Inventory and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Scale Scale will be used to collect data.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-17
• Study First Submitted QC: 2023-05-17
• Study First Posted: 2023-05-25
• Study Start: 2023-07-11
• Primary Completion: 2024-06-05
• Study Completion: 2024-11-06
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-06
• Last Update Posted: 2025-02-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Be 18 years or older
2. Being able to read and write
3. Being oriented to place, time, person
4. Not having a hearing problem
5. Not having a speech problem
6. Being able to use the phone
7. Primary medical diagnosis is colorectal cancer
8. Patients who have completed primary treatment for colorectal cancer and are followed up
9. Not to relapse
10. Being in remission
11. Having a Karnofsky Performance Scale of 70% and above and being followed on an outpatient basis

Exclusion Criteria

1.Patients with cognitive problems

Exclusion Criteria from the Sample During the Research:

1. Patient's wish to leave the study
2. Continuing the outpatient follow-up of the patient in the medical oncology outpatient clinic of another institution

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CRCaSSM	CRCaSSM	CRCaSSM

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Quality of Life Level on the EORTC QLQ-CR29 Quality of Life	Baseline and 12th week	EORTC QLQ-CR29 The QLQ-CR29 includes 29 items that evaluate symptoms (gastrointestinal, urinary, pain and others) and functional areas (sexual, body image and others). Similar to the EORTC QLQ-C30, the QLQ-CR29 has a Likert scale of four response categories (item 48 requires a yes or no answer). All patient-rated scores are linearly converted into a scale from 0 to 100 for both the QLQ-C30 and QLQ-CR29.
Change from Baseline in symptom management at week 12	Baseline, 4th week, 8th week and 12th week	Memorial Symptom Assessment Scale (MSAS): The Memorial Symptom Assessment Scale is a multidimensional self-report questionnaire that evaluates 32 physical and psychological symptoms according to their frequency, severity and distress/bother to the person in the past week.The total score is the average of the responses to the distress scale items and and ranges from 0 to 4 with higher values indicating greater distress experienced from symptoms.
Change from Baseline in Fear of Cancer Recurrence at week 12	Baseline and 12th week	Fear of Cancer Recurrence Inventory (FCRI): It consists of 42 items with seven subscales triggers, severity, psychological distress, coping strategies, functioning impairments, insight, reassurance. FCRI, is a Likert-type scale that ranges from 0 (not at all/never) to 4 (all the time/a great deal). Increasing scores received from the scale demonstrate a high level of FCR. The minimum score to be taken from the scale is 0, and the maximum score is 168.
Change from Baseline in Quality of Life Level on the EORTC QLQ-C30 Quality of Life Scale at week 12	Baseline and 12th week	EORTC QLQ-C30 Quality of Life Scale(European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire): This Scale was developed to measure the quality of life of patients with cancer. It includes 30 questions and three sub-dimensions: General Well-Being, Functional Difficulties, and Symptom Control. The maximum score on the scale is 100, and the minimum is 0. High scores on the functional sub-dimension indicate good/healthy functional status, high scores on the symptom sub-dimension indicate high levels of symptoms and/or problems, and high scores on the global health status/quality of life sub-dimension indicate good quality of life.

Trial Locations

Locations (1)

Akdeniz University Hospital; 🇹🇷 Antalya, Turkey